SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 384,448.23 |
Enterprise Value ($M) | 396,977.23 |
Book Value ($M) | 70,158.00 |
Book Value / Share | 29.14 |
Price / Book | 5.48 |
NCAV ($M) | -52,721.00 |
NCAV / Share | -21.90 |
Price / NCAV | -7.29 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | 0.13 |
Return on Assets (ROA) | 0.08 |
Return on Equity (ROE) | 0.20 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 0.86 |
Current Ratio | 1.11 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 55,893.00 |
Assets | 180,104.00 |
Liabilities | 108,614.00 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 88,821.00 |
Operating Income | 21,249.00 |
Net Income | 14,066.00 |
Earnings Per Share Diluted | n/a |
Earnings Per Share Basic | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 24,266.00 |
Cash from Investing | -18,599.00 |
Cash from Financing | -3,132.00 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | Vanguard Group Inc | 9.53 | -7.07 | |
13G/A | State Street Corp | 5.52 | -6.64 | |
13G/A | BlackRock, Inc. | 7.70 | -6.28 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
1,808,078 | 9,426,087 | 19.18 | |
1,162,071 | 5,305,377 | 21.90 | |
1,812,690 | 6,212,318 | 29.18 | |
1,227,417 | 6,164,820 | 19.91 | |
(click for more detail) |
Similar Companies | |
---|---|
EBS – Emergent BioSolutions Inc. | ELAN – Elanco Animal Health Incorporated |
HYAC – Haymaker Acquisition Corp. 4 | LLY – Eli Lilly and Company |
MRK – Merck & Co., Inc. |